中国药物警戒 ›› 2025, Vol. 22 ›› Issue (8): 920-923.
DOI: 10.19803/j.1672-8629.20240986

• 安全与合理用药 • 上一篇    下一篇

金花清感颗粒治疗轻型流感临床应用的Meta分析

应婕1, 徐霄龙2,3,4, 李博2,3, 刘腾文5, 刘清泉2,3,4*   

  1. 1北京中医药大学临床医学院,北京 100020;
    2首都医科大学附属北京中医医院急诊科,北京 100010;
    3北京市中医药研究所,北京 100010;
    4首都医科大学临床医学实验室,北京 100010;
    5成都中医药大学基础医学院,四川 成都 610075
  • 收稿日期:2024-12-12 出版日期:2025-08-15 发布日期:2025-08-13
  • 通讯作者: *刘清泉,男,教授·博导,主任医师,急危重症与新发突发传染病。E-mail: liuqingquan2003@126.com
  • 作者简介:应婕,女,硕士,中西医结合临床。
  • 基金资助:
    国家自然科学基金资助项目（82141202）

Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis

YING Jie1, XU Xiaolong2,3,4, LI Bo2,3, LIU Tengwen5, LIU Qingquan2,3,4*   

  1. 1Clinical Medical College of Beijing University of Chinese Medicine, Beijing 100020, China;
    2Emergency Department, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, China;
    3Beijing Institute of Traditional Chinese Medicine, Beijing 100010, China;
    4Laboratory for Clinical Medicine, Capital Medical University, Beijing 100010, China;
    5Basic Medical College, Chengdu University of Traditional Chinese Medicine, Chengdu Sichuan 610075, China
  • Received:2024-12-12 Online:2025-08-15 Published:2025-08-13

PDF (PC)

6

摘要： 目的 探讨金花清感颗粒在轻型流感治疗中的临床作用,为临床运用提供参考。方法 检索PubMed、Embase、Cochrane Library、Web of Science、中国知网、维普网和万方数据库,检索时间从建库至2024年8月30日。根据Cochrane系统评价方法,纳入金花清感颗粒治疗轻型流感的随机对照试验,使用Stata 16.0软件执行Meta分析。结果 纳入1 085例患者。低剂量金花清感颗粒（每次5 g）用药3 d时,中医证候有效率较安慰剂高9.23%[95%CI（5.30, 13.15）],但需关注潜在发表偏倚;退热率较安慰剂高7.31%[95%CI（3.04, 11.59）],Begg检验未提示发表偏倚;用药5 d,中医证候改善无明显差异,退热率较安慰剂高1.92%[95%CI（-2.74, 6.58）],Begg检验未提示发表偏倚。高剂量金花清感颗粒（每次10 g）在改善中医证候和退热方面未显示优势。结论 金花清感颗粒治疗轻症流感有效,在改善临床症状、缩短发热时间方面具备优势。

关键词: 轻型流感, 金花清感颗粒, Meta分析, 随机对照试验, 循证医学

Abstract: Objective To explore the clinical efficacy of Jinhua Qinggan granules in the treatment of mild influenza. Methods Such databases as PubMed, Embase, Web of Science, Cochrane Library, CNKI, VIP and Wanfang were searched for related literature that was collected from the inception to August 30, 2024. Randomized controlled trials (RCTs) about Jinhua Qinggan granules used for mild influenza were included following Cochrane systematic review guidelines. Meta-analysis was performed using Stata 16.0. Results A total of 1 085 patients were included. For the low-dose Jinhua Qinggan granules (5 g/dose), the efficacy of syndrome-based treatment with TCM was 9.23% higher than that of the placebo [95%CI (5.30, 13.15)] after three days of treatment despite potential publication bias. The fever resolution rate of three days of treatment with low-dose Jinhua Qinggan granules was 7.31% higher than that of placebo [95%CI (3.04, 11.59)], with no publication bias detected by Begg's test. After five days of treatment, there was no significant difference in improvement of TCM syndromes compared to the placebo, but the fever resolution rate was 1.92% higher (95%CI [-2.74, 6.58]), with no publication bias observed by Begg's test. High-dose Jinhua Qinggan granules (10 g/dose) showed no advantage in improving TCM syndromes or the fever resolution rate compared to the control groups. Conclusion Jinhua Qinggan granules prove to be effective for mildinfluenza by alleviating TCM clinical symptoms and accelerating fever resolution.

Key words: Mild Influenza, Jinhua Qinggan Granules, Meta-Analysis, Randomized Controlled Trial, Evidence-Based Medicine

中图分类号: